| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
Ruscogenin (0.01–40 μM; 24 hours) can improve bEnd.3 cell viability when treated with OGD/R [1]. Ruscogenin (0.01–10 μM; 24 hours) can improve bEnd.3 cell viability when treated with OGD/R [1]. It has the ability to decrease the TXNIP/NLRP3 dye signal, block the expression of IL-Iβ and Caspase-1, and restore endothelial cell barrier leakage [1]. OGD/R-treated bEnd.3 treated with ruscovenin (0.01-10 μM; 4 hours)
|
|---|---|
| ln Vivo |
Ruscogenin (10 mg/kg; gavage; once) reduces MCAO/R-induced brain tissue damage, stops IL-1β and Caspase-1 production, and prevents TXNIP/NLRP3 activation [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: bEnd.3 cell Tested Concentrations: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM Incubation Duration: 24 hrs (hours) Experimental Results: It shows that the decrease in cell viability induced by OGD/R in bEnd.3 cells is Dramatically restored. Immunofluorescence [1] Cell Types: bEnd.3 Cell Tested Concentrations: 0.1 μM, 1 μM, 10 μM Incubation Duration: 24 h Experimental Results: Shows increased TEER value and inhibits fluorescein sodium permeability. Western Blot Analysis[1] Cell Types: bEnd.3 Cell Tested Concentrations: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM Incubation Duration: 24 h Experimental Results: IL-1β and Caspase expression down-regulated -1 protein, and inhibited the expression of NLRP3 and TXNIP. Immunofluorescence[1] Cell Types: bEnd.3 Cell Tested Concentrations: 0.01 μM, 0.1 μM, 1 μM, 10 μM, 20 μM, 40 μM Incubation Duration: 4 hrs (hours) Experimental Results: Demonstrated diminished ROS production. |
| Animal Protocol |
Animal/Disease Models: MCAO/R mice [1]
Doses: 10mg/kg Route of Administration: po (oral gavage) (ig) Experimental Results: Smaller infarct size, improved histopathological damage by reducing cell loss, CBF (brain blood flow) Dramatically increased in the model group. Results Compared with the model group, the expressions of IL-1β, Caspase-1, NLRP3 and TXNIP were inhibited. |
| References |
|
| Additional Infomation |
Ruscogenin is a triterpenoid.
Ruscogenin has been reported in Tribulus terrestris, Cordyline banksii, and other organisms with data available. |
| Molecular Formula |
C27H42O4
|
|---|---|
| Molecular Weight |
430.6200
|
| Exact Mass |
430.308
|
| CAS # |
472-11-7
|
| PubChem CID |
441893
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
563.1±50.0 °C at 760 mmHg
|
| Melting Point |
198-202ºC
|
| Flash Point |
294.4±30.1 °C
|
| Vapour Pressure |
0.0±3.5 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
4.29
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
31
|
| Complexity |
779
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5([C@@H](C[C@@H](C6)O)O)C)C)C)OC1
|
| InChi Key |
QMQIQBOGXYYATH-IDABPMKMSA-N
|
| InChi Code |
InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1
|
| Chemical Name |
(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,14R,16R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14,16-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~58.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3222 mL | 11.6112 mL | 23.2223 mL | |
| 5 mM | 0.4644 mL | 2.3222 mL | 4.6445 mL | |
| 10 mM | 0.2322 mL | 1.1611 mL | 2.3222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
